Introducing

The first and only three-chamber bag for parenteral nutrition (PN)

NEW KABIVEN®
(Amino Acids, Electrolytes, Dextrose, and Lipid Injectable Emulsion), for intravenous use

NEW PERIKABIVEN®
(Amino Acids, Electrolytes, Dextrose, and Lipid Injectable Emulsion), for intravenous use

FRESENIUS KABI
caring for life
The Kabiven three-chamber bag has the components clinicians have relied on for years

- **DEXTROSE**
  - Provides a moderate dose of carbohydrates

- **AMINO ACIDS AND ELECTROLYTES**
  - A source of essential and nonessential amino acids and balanced electrolytes

- **LIPIDS (INTRALIPID®)**
  - A reliable source of lipids used worldwide for 50 years; registered in the U.S. since 1975

- Clear container and overwrap allows for quick visual inspection
- Up to 24 months shelf-life at 20 - 25°C (68 - 77°F)

✓ PVC-free
✓ Non-DEHP
✓ Not made with natural rubber latex
Simplify parenteral nutrition

• Standardization of parenteral nutrition using commercial premixed bags can help support PN safety for your patients \(^1\)

• Kabiven and Perikabiven meet the nutritional needs of most PN patients \(^2, 3\)

• Convenient to store and can be dispensed by pharmacy anytime, including nights and weekends

<table>
<thead>
<tr>
<th>PRODUCT INFORMATION</th>
<th>Kabiven (central PN)</th>
<th>Perikabiven (peripheral or central PN)</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDC</td>
<td>63323-712-10</td>
<td>63323-714-14</td>
</tr>
<tr>
<td></td>
<td>63323-712-15</td>
<td>63323-714-19</td>
</tr>
<tr>
<td></td>
<td>63323-712-20</td>
<td>63323-714-24</td>
</tr>
<tr>
<td>Product number</td>
<td>831220310</td>
<td>831231310</td>
</tr>
<tr>
<td></td>
<td>831221310</td>
<td>831232310</td>
</tr>
<tr>
<td></td>
<td>831222310</td>
<td>831233310</td>
</tr>
<tr>
<td>Volume / Calories</td>
<td>1026 mL/ 870 kcal</td>
<td>1440 mL/ 970 kcal</td>
</tr>
<tr>
<td></td>
<td>1540 mL/ 1310 kcal</td>
<td>1920 mL/ 1300 kcal</td>
</tr>
<tr>
<td></td>
<td>2053 mL/ 1745 kcal</td>
<td>2400 mL/ 1620 kcal</td>
</tr>
<tr>
<td></td>
<td>2566 mL/ 2180 kcal</td>
<td></td>
</tr>
<tr>
<td>Unit of sale</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>3</td>
</tr>
</tbody>
</table>

Please see package insert including **Boxed Warning** for full prescribing information available at www.KabivenUSA.com.

---

2. Kabiven Prescribing Information, Fresenius Kabi, USA, LLC, 2014
3. Perikabiven Prescribing Information, Fresenius Kabi, USA, LLC 2014

---

**To order call:** 1.888.386.1300

www.KabivenUSA.com

www.Fresenius-Kabi.us

**NEW KABIVEN® (Amino Acids, Electrolytes, Dextrose, and Lipid Injectable Emulsion), for intravenous use**

**NEW PERIKABIVEN® (Amino Acids, Electrolytes, Dextrose, and Lipid Injectable Emulsion), for intravenous use**
Kabiven® and Perikabiven® three chamber bags must be mixed prior to infusion. For admixing instructions see DIRECTIONS FOR ACTIVATING THE BAG in the Prescribing Information available at www.KabivenUSA.com.

INDICATIONS AND LIMITATIONS OF USE
• Kabiven and Perikabiven are each indicated as a source of calories, protein, electrolytes and essential fatty acids for adult patients requiring parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. Kabiven and Perikabiven may be used to prevent essential fatty acid deficiency or treat negative nitrogen balance in adult patients.
• Kabiven is indicated for intravenous infusion into a central vein.
• Perikabiven is indicated for intravenous infusion into a peripheral or central vein.
• Neither Kabiven nor Perikabiven is recommended for use in pediatric patients < 2 years, including preterm infants because the fixed content of the formulations do not meet the nutritional requirements in this age group.

IMPORTANT SAFETY INFORMATION

WARNING
• Deaths in preterm infants have been reported in literature.
• Autopsy findings included intravascular fat accumulation in the lungs.
• Preterm and low birth weight infants have poor clearance of intravenous lipid emulsion and increased free fatty acid plasma levels following lipid emulsion infusion.

CONTRAINDICATIONS
• Known hypersensitivity to egg, soybean proteins, peanut proteins, corn or corn products, or to any of the active substances or excipients.
• Severe hyperlipidemia or severe disorders of lipid metabolism with serum triglycerides >1000 mg/dL.
• Inborn errors of amino acid metabolism.
• Cardiopulmonary instability.
• Hemophagocytic syndrome.

WARNINGS AND PRECAUTIONS
• Kabiven is hypertonic and may cause vein irritation, vein damage and even thrombosis if infused in a peripheral vein. Only infuse Kabiven into a central vein.
• Monitor for signs or symptoms of hypersensitivity reactions and discontinue infusion if reactions occur.
• Monitor patient closely for signs and symptoms of infection, hypertriglyceridemia, hyperglycemia and refeeding complications.
• Monitor laboratory parameters for alterations in electrolytes, liver and renal impairment, fluid status and coagulation parameters. Adjust rate and dose of Kabiven and Perikabiven according to clinical status.

To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC, Vigilance & Medical Affairs at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information, including Boxed Warning, for Kabiven and Perikabiven available at www.KabivenUSA.com.

To order call: 1.888.386.1300

www.KabivenUSA.com

www.Fresenius-Kabi.us